Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Current evidence from clinical trials and preclinical studies suggests that both Lacticaseibacillus rhamnosus + Limosilactobacillus reuteri are associated with anti-obesity effects, but research testing the combination of these two specifically in the context of adiposity or obesity is limited in humans. Most available data come from studies investigating either strain separately or as part of multispecies probiotic or synbiotic formulations.
For the double-blind, randomized clinical prevention trial NCT07013409, no published results were found as of September 2025
see also:
[Adiposity / Obesity & Dr…